[1] |
ZHAO Yihan, LI Ruochen, LIN Yansong.
Current status and prospect of diagnosis and treatment of bone metastasis of thyroid cancer
[J]. China Oncology, 2025, 35(1): 12-20.
|
[2] |
ZHANG Zhiyue, HE Huijing, SHAN Guangliang, LIN Yansong.
Research progress in epidemiology and risk factors of thyroid cancer
[J]. China Oncology, 2025, 35(1): 21-29.
|
[3] |
GENG Qianqian, YANG Aimin.
Progress and prospect on treatment for radioiodine-refractory thyroid cancer
[J]. China Oncology, 2025, 35(1): 30-39.
|
[4] |
LI Ruping, YANG Hui.
Current status and future prospects of clinical trials for radioiodine-refractory thyroid cancer
[J]. China Oncology, 2025, 35(1): 40-48.
|
[5] |
WANG Renfei, LU Gaixia.
The unique value and controversy of nuclear medicine molecular imaging in the evaluation of radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 49-57.
|
[6] |
LIN Qiuyu, WANG Yuxin, LIN Chenghe.
Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 58-67.
|
[7] |
SHEN Jie, LIU Wanlin, WANG Zezhou, MU Sibo, MO Miao, ZHOU Changming, YUAN Jing, WANG Yu, ZHENG Ying, JI Qinghai.
Survival and cause-of-death analysis of 55 thousand thyroid cancer cases in China from a large single institution hospital-based cancer registry database
[J]. China Oncology, 2025, 35(1): 68-76.
|
[8] |
JIANG Xiaotong, LIU Jinchuan, ZHANG Yingqiang, WANG Tong, GUO Ning, SUN Yuqing, SHI Cong, YAN Bing, LIN Yansong.
The role of diagnostic whole body scan in decision-making of 131I treatment for differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 77-84.
|
[9] |
LIU Qi, CHANG Cai, LI Jiawei.
Research progress on the correlation between imaging features and the molecular subtype, histopathology, clinical prognosis of ductal carcinoma in situ of the breast
[J]. China Oncology, 2024, 34(2): 201-209.
|
[10] |
CHEN Gang, ZHANG Shunkang, GUO Shaowen, LU Yue, SUN Liyun, SHEN Lei, WANG Cheng.
Cohort study on correlation between serum TTF-1, PAX-8 and thyroid dysfunction after breast cancer post-operative radiation therapy
[J]. China Oncology, 2024, 34(12): 1100-1107.
|
[11] |
PAN Yijin, SHI Cong, SUN Yuqing, SUN Di, ZHAO Yihan, ZHANG Jin, LIN Yansong.
Global trends of 131I-therapy for differentiated thyroid cancer in children and adolescents: a bibliometric analysis (1993-2003)
[J]. China Oncology, 2024, 34(12): 1123-1133.
|
[12] |
XUE Liqiong, GUO Ye, CHEN Libo.
Expert consensus on the management of adverse events in patients receiving targeted agents for advanced thyroid cancer (2023 edition)
[J]. China Oncology, 2023, 33(9): 879-888.
|
[13] |
ZHANG Haoting, ZHENG Jing, FU Mengjiao, ZHOU Jianying.
Research progress on thyroid dysfunction induced by immunotherapy for lung cancer
[J]. China Oncology, 2023, 33(7): 701-706.
|
[14] |
YUAN Xinyue, YAO Yao, CHENG Shuai, ZHENG Xin, ZHANG Yuan.
Clinical study on high-risk factors for contralateral lymph node metastasis in unilateral papillary thyroid carcinoma
[J]. China Oncology, 2023, 33(6): 619-628.
|
[15] |
QU Ning, WANG Yuting, MA Ben, WANG Yu.
Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022
[J]. China Oncology, 2023, 33(5): 423-430.
|